Drug Type Small molecule drug |
Synonyms ARG, GBS-01, NSC-206269 |
Target |
Mechanism ADIPOR1 agonists(Adiponectin receptor protein 1 agonists), PP2A stimulants(Protein phosphatase 2A stimulants), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H24O6 |
InChIKeyNQWVSMVXKMHKTF-JKSUJKDBSA-N |
CAS Registry7770-78-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Arctigenin |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 2 | JP | - | - |
Pancreatic Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Diabetic Nephropathies | Preclinical | CN | 15 Nov 2016 | |
Diabetic Nephropathies | Preclinical | - | 15 Nov 2016 | |
Inflammation | Preclinical | US | 01 Feb 2016 | |
Peanut Hypersensitivity | Preclinical | US | 01 Feb 2016 |
Not Applicable | Prader-Willi Syndrome GH peak | IGF1 levels | 28 | hmichsiazo(jwbcduailx) = sttabycvhb jlwhsrpcfr (txipcmmldq ) | - | 18 Sep 2014 | ||
Phase 1 | 15 | voiiksdepj(dnydpmlrbn) = qaevaupdih tvvrdznfzx (mdccxgftni ) View more | - | 20 May 2013 | |||
GBS-01 7.5g | voiiksdepj(dnydpmlrbn) = lreqhmdpgn tvvrdznfzx (mdccxgftni ) View more |